Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Lawrence A Leiter
  • Stephen C Bain
  • Irene Hramiak
  • Esteban Jódar
  • Sten Madsbad
  • Theis Gondolf
  • Thomas Hansen
  • Ingrid Holst
  • Ildiko Lingvay
View graph of relations

BACKGROUND: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects of gender, age and baseline CV risk on outcomes are important considerations for further study.

METHODS: Subjects were grouped according to gender, age (50-65 years and > 65 years), and CV risk profile at baseline (prior myocardial infarction [MI] or stroke vs no prior MI or stroke, and established CV disease [CVD] vs CV risk factors alone, including subjects with chronic kidney disease). Time to MACE and its individual components (CV death, nonfatal MI, nonfatal stroke), hospitalization for unstable angina or heart failure, and revascularization (coronary and peripheral) were analyzed for all subgroups. Additional analyses were performed for gender and age to investigate change from baseline in HbA1c and body weight, as well as tolerability.

RESULTS: A total of 3297 subjects were included. The majority of subjects (60.7%) were male; 43% were > 65 years of age; 41.5% had a history of MI or stroke; and 76.8% had established CVD. Compared with placebo, semaglutide reduced the risk of the first occurrence of MACE and each MACE component consistently across all subgroups (gender, age, and baseline CV risk profile). Revascularizations, HbA1c and body weight were also reduced consistently across all subgroups compared with placebo. Gastrointestinal adverse events in all treatment groups were more common among women than men, but rates of premature treatment discontinuation were similar for both genders.

CONCLUSIONS: In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile. Trial registry, Identifying number: NCT01720446, Date of registration: October 29, 2012.

Original languageEnglish
Article number73
JournalCardiovascular Diabetology
Issue number1
Publication statusPublished - 6 Jun 2019

    Research areas

  • Age, Baseline cardiovascular risk, Cardiovascular events, Cardiovascular outcome trial, Gender, Semaglutide, SUSTAIN 6, Type 2 diabetes

ID: 57329216